

REF: MDOL/CS-SE/2021- 22/007

May 20, 2021

To,

Listing Department

BSE Ltd

1st Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001.

Scrip Code: 532637

Listing Department

National Stock Exchange of India Limited

"Exchange Plaza", 5th Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

Symbol: MANGALAM


Sub: Outcome of the Board Meeting held on Thursday, May 20, 2021

Dear Sir / Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we have to inform you that the Board of Directors of the Company, in their meeting held today i.e., Thursday, May 20, 2021 has *inter-alia* approved the Audited Financial Results (Standalone) for the quarter and year ended March 31, 2021 pursuant to Regulation 33 of the Listing Regulations. A copy of the said results, notes thereto and Auditor's Report is enclosed for your records.

We hereby declare that the Auditors have expressed a modified opinion in the Audit Report on the Standalone Audited Financial Results for the quarter and year ended March 31, 2021 and as required we submit the Annexure – I in the prescribed format thereby furnishing Statement of impact of Audit Qualifications (for Audit Report with modified opinion).

Further please note that the Company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations.



Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



The meeting of Board of Directors of the Company commenced at 2:30 P.M. and concluded at 4:10 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

**Audited Financial Results for the Year Ended 31st March 2021 approved and taken on record by the Board at their meeting dated
20th May, 2021**

Sr.No	Particulars	Quarter Ended			Year Ended	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		Audited	Unaudited	Audited	Audited	Audited
A) Part-1 Statement of Audited Financial Results for the Year Ended March 31, 2021						
1	Revenue from Operations	9,078.70	8,868.73	8,809.46	38,014.06	28,235.36
2	Other Income	211.38	126.78	45.33	472.06	118.12
3	Total Revenue(1+2)	9,290.08	8,995.51	8,854.79	38,486.12	28,353.48
4	Expenses					
	(a) Cost of Materials Consumed	5,468.93	5,354.36	5,279.54	25,601.72	17,807.14
	(b) Purchase of Stock in trade	0.00	0.00			0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	679.82	278.35	1,084.22	(423.26)	1,727.66
	(d) Employee Benefits Expenses	846.96	741.19	705.66	2,987.95	2,604.41
	(e) Finance Costs	221.57	234.82	246.29	932.61	1,040.47
	(f) Depreciation & amortization expenses	251.53	233.36	209.61	917.53	821.78
	(g) Other Expenses	1,137.15	1,234.50	1,024.11	4,517.67	3,726.81
	Total Expenses	8,605.96	8,076.58	8,549.43	34,534.22	27,728.27
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	684.12	918.93	305.36	3,951.91	625.21
6	Exceptional items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	684.12	918.93	305.36	3,951.91	625.21
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	684.12	918.93	305.36	3,951.91	625.21
10	Tax Expenses					
	Current Tax	152.41	204.42	34.69	926.78	110.10
	Less: MAT credit entitlement / reversal	88.25	71.09	(29.33)		(104.74)
	Deferred Tax	228.04		(205.40)	228.04	(205.40)
11	Net Profit(+)/Loss(-) after Tax (9-10)	215.42	643.42	505.40	2,797.09	825.25
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	5.51	(33.42)	0.32	(94.77)	2.32
13	Total Comprehensive Income	220.93	610.00	505.72	2,702.31	827.57
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				11,513.36	8,811.05
16	Earnings Per Share (EPS) (of Rs 10/-each not annualised):					
	(a) Basic	1.36	4.07	3.19	17.67	5.21
	(b) Diluted	1.36	4.07	3.19	17.67	5.21

Notes :

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on May 20, 2021. The Statutory Auditors have expressed an modified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Code on Social Security, 2020('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent December 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- Hon'ble Securities Appellate Tribunal granted the interim reliefs vide its Order dated December 10, 2020 (SAT Interim Order) by directing that the effect and operation of the order passed by Securities and Exchange Board of India (SEBI) through its whole-time member dated September 22, 2020 shall remain stayed provided the Company and entities / individuals part of the promoter and promoter group (appellants) deposit a sum of Rs. 25 Lakhs before the SEBI within 4 (four) weeks from the date of SAT Interim Order. The amount so deposited shall be subject to the result of the appeal. The application for stay filed by appellants was disposed of. Accordingly, Appellants had deposited a sum of Rs. 25 Lakhs before the SEBI (including Rs. 2.92 Lakhs deposited by the Company). The final decision in the matter is awaited.
- The figures for the quarter ended 31st March, 2021 and 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

PARAG
RAMAN
HANGEKAR
Date: 2021.05.20
15:38:38 +05'30'

Place: Mumbai
Date: 20th May, 2021

On behalf of Board of Directors
For Marigalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)

